VRDN

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

• FDA Grants Breakthrough Therapy Designation to Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025

News

• Viridian Therapeutics reported positive Phase 3 REVEAL 2 results for elegrobart in thyroid eye diseaseMay 5, 2026
• Viridian Therapeutics announces BLA acceptance and priority review for veligrotug in thyroid eye diseaseDec 22, 2025
• Viridian Therapeutics announces successful October submission of biologics license application to U.S. FDA for Veligrotug in thyroid eye diseaseNov 3, 2025
• Viridian Therapeutics announces completion of enrollment in both REVEAL clinical trials and positive portfolio updatesSep 15, 2025
• Viridian Therapeutics announces collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize Veligrotug and VRDN-003 in Japan, including upfront $70M and up to $315M milestone paymentsJul 30, 2025